Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 602-2265 Upper Middle Road East OAKVILLE ON L6H 0G5 |
Tel: | 1-289-9100855 |
Website: | https://www.cardiolrx.com |
IR: | See website |
Key People | ||
David Elsley President, Chief Executive Officer, Director | Christopher Waddick Chief Financial Officer, Corporate Secretary, Director | Bernard Lim Chief Operating Officer | Andrew Hamer Chief Medical Officer, Head of Research and Development |
Business Overview |
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart. |
Financial Overview |
For the nine months ended 30 September 2023, Cardiol Therapeutics Inc revenues was not reported. Net loss decreased 12% to C$20.5M. Lower net loss reflects Administration - Balancing value decrease of 49% to C$8.5M (expense), Research and development - Balancing val decrease of 23% to C$9.9M (expense), Interest income increase from C$653K to C$1.6M (income). |
Employees: | 17 as of Dec 31, 2022 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $111.02M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$30.60M as of Sep 30, 2023 |
Net annual income (TTM): | -$28.01M as of Sep 30, 2023 |
Free cash flow (TTM): | -$27.74M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 68,168,708 as of Mar 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |